ACOX3 represents a dual diagnostic and prognostic biomarker with broad pan-cancer relevance, exhibiting distinct immune correlates and therapeutic potential.

1 day ago

Journal • Pan tumor

CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)

AZD6482 • TGX-221

Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss (clinicaltrials.gov)

P1/2, N=27, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027

4 days ago

Trial completion date • Trial primary completion date

PTEN (Phosphatase and tensin homolog)

Keytruda (pembrolizumab) • GSK2636771

18d

Integrative bioinformatics and machine learning approach unveils potential biomarkers linking coronary atherosclerosis and glutamine metabolism-associated gene. (PubMed, J Cardiothorac Surg)

This study successfully discovered nine GlnMgs that are associated with AS. These findings provide valuable insights into potential novel biomarkers for AS and offer prospects for monitoring disease progression.

18 days ago

Journal

MIR21 (MicroRNA 21) • NOS3 (Nitric oxide synthase 3) • SIRT4 (Sirtuin 4)

acalisib (GS-9820)

18d

STARS: Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke (clinicaltrials.gov)

P2, N=80, Recruiting, The Florey Institute of Neuroscience and Mental Health | Suspended --> Recruiting

18 days ago

Enrollment open

AZD6482

24d

Co-STARS: Safety, Tolerability and Efficacy of Adjunctive TBO-309 in Reperfusion for Stroke With Tandem Occlusion (clinicaltrials.gov)

P2, N=78, Recruiting, ThromBio Pty. Ltd. | Not yet recruiting --> Recruiting

24 days ago

Enrollment open

AZD6482

PDCD1 as a targetable immune checkpoint hub: therapeutic insights for ibrutinib-resistant CLL management. (PubMed, Clin Exp Med)

Using two independent datasets (GSE249956 and GSE98206), differentially expressed genes (DEGs) were identified between ibrutinib-resistant and sensitive CLL samples. In the broader context, PD-1 expression in CLL cells is linked to active proliferation and immune escape. Overall, our findings emphasize PDCD1's central role in ibrutinib resistance through immune checkpoint pathways and support the rationale for combining BTK inhibitors with immune checkpoint blockade therapies in resistant CLL cases.

1 month ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-1 (Programmed cell death 1) • ITGB2 (Integrin Subunit Beta 2) • CD1C (CD1c Molecule)

PD-L1 expression

Imbruvica (ibrutinib) • acalisib (GS-9820)

PI3K inhibitors: Efficacy in diverse cancer forms. (PubMed, Cancer Treat Res Commun)

The PI3K inhibitors GDC-0032 and INK1117 for PI3K-α and AZD8186 for PI3K-β are now being studied in clinical trials. Research on the clinical development, therapeutic utility, and structural insights of new PI3K inhibitors is the main emphasis of this review. The inhibitors have been shown promising anticancer activity relationships.

1 month ago

Review • Journal

PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta)

taselisib (GDC-0032) • AZD8186 • serabelisib (MLN1117)

2ms

EAY131-N: Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) (clinicaltrials.gov)

P2, N=24, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2025 --> Dec 2026

2 months ago

Trial completion date

PTEN (Phosphatase and tensin homolog)

GSK2636771

2ms

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov)

P1, N=23, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Oct 2026

2 months ago

Trial completion date

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PTEN (Phosphatase and tensin homolog) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta)

ER positive • HR positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive

docetaxel • AZD8186

2ms

EAY131-P: Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) (clinicaltrials.gov)

P2, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2025 --> Dec 2026

2 months ago

Trial completion date

PTEN (Phosphatase and tensin homolog)

GSK2636771

2ms

Mendelian randomization combined with single-cell sequencing analysis revealed prognostic genes related to myeloid cell differentiation in prostate cancer and experimental verification. (PubMed, Front Immunol)

The HRG and LRG suggested notable differences in sensitivity to 86 drugs such as AZD8186...The in vitro results were consistent with the results of bioinformatics analysis, indicating that the analysis results were reliable. This study identified 5 prognostic genes and a risk model, suggesting a fresh thought on the subsequent development of PCa related drugs.

2 months ago

Journal

FASN (Fatty acid synthase) • TLR3 (Toll Like Receptor 3) • RACGAP1 (Rac GTPase activating protein 1) • BMP2 (Bone Morphogenetic Protein 2)

AZD8186

3ms

Moreover, TGX-221 represents a promising novel therapeutic candidate, while HS2ST1 serves as a potential prognostic biomarker. These findings collectively provide tools for risk stratification and targeted therapy, advancing precision oncology for WT.

3 months ago

Journal

PPP3CA (Protein Phosphatase 3 Catalytic Subunit Alpha)

TGX-221